ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2549

Characterizing the RPTPσ Mediated Proteoglycan Switch As a Target for Rheumatoid Arthritis Therapy

Karen M. Doody1, Stephanie M. Stanford1, Mattias N. D. Svensson1, Cristiano Sacchetti1, Gary S. Firestein2, A. Radu Aricescu3 and Nunzio Bottini1,4, 1Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 3Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 4Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Fibroblasts, proteoglycans and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:   RPTPσ (gene PTPRS) is a protein tyrosine phosphatase that binds heparan sulfate- and chondroitin sulfate-containing proteoglycans with its extracellular immunoglobulin domains 1 and 2 (Ig1&2). RPTPσ is expressed at minimal or low levels in immune cells, while in neurons the competition between heparan sulfate and chondroitin sulfate for RPTPσ binding controls axon outgrowth and is called the proteoglycan switch. We recently reported that RPTPσ is highly expressed in fibroblast-like synoviocytes (FLS) and the proteoglycan switch exists in these cells. Treatment of FLS with decoy RPTPσ Ig1&2 competes with surface heparan sulfate proteoglycans, which flips the proteoglycan switch and reduces rheumatoid arthritis (RA) FLS migration, invasion and attachment to cartilage. Systemic administration of RPTPσ Ig1&2 reduces arthritis severity and cartilage damage in the K/BxN serum transfer mouse model of RA. To further characterize RPTPσ Ig1&2 as a putative FLS-targeting treatment for RA, we tested its selectivity for FLS, as well as its effectiveness in an additional mouse model of arthritis.

Methods: Migration was assessed using a scratch-wound assay with RA FLS and normal human dermal fibroblasts (NHDF). Collagen production in NHDF was assessed by measuring collagen 1A2 mRNA expression in TGFβ-stimulated cells. RPTPσ  and heparan sulfate proteoglycan mRNA expression were measured by qPCR. Surface expression of heparan sulfate was assessed by flow cytometry. Collagen antibody-induced arthritis (CAIA) was induced by injection of mice with an anti-collagen antibody cocktail (ArthritoMab®).

Results:  RPTPσ Ig1&2 decreased migration of RA FLS by 27%, but did not affect migration of NHDF. This was not due to differences in PTPRS expression; however, surface heparan sulfate levels and expression of heparan sulfate proteoglycans were higher in RA FLS (> 4-fold and > 2-fold increase, respectively). RPTPσ Ig1&2 did not affect collagen production by NHDF upon TGFβ stimulation, a characteristic function of these cells important for wound-healing. Finally, RPTPσ Ig1&2 administration decreased arthritis severity by 30% in the CAIA mouse model of RA.

Conclusion: RPTPσ Ig1&2 treatment ameliorates arthritis in multiple models by selectively targeting FLS due to their high expression of heparan sulfate proteoglycans. These results support further testing of RPTPσ Ig1&2 alone and in combination with conventional immune-targeting RA therapies.


Disclosure: K. M. Doody, None; S. M. Stanford, None; M. N. D. Svensson, None; C. Sacchetti, None; G. S. Firestein, None; A. R. Aricescu, None; N. Bottini, None.

To cite this abstract in AMA style:

Doody KM, Stanford SM, Svensson MND, Sacchetti C, Firestein GS, Aricescu AR, Bottini N. Characterizing the RPTPσ Mediated Proteoglycan Switch As a Target for Rheumatoid Arthritis Therapy [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/characterizing-the-rptp-mediated-proteoglycan-switch-as-a-target-for-rheumatoid-arthritis-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizing-the-rptp-mediated-proteoglycan-switch-as-a-target-for-rheumatoid-arthritis-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology